Rotavirus vaccines

Indian Journal of Medical Microbiology

Volumn 24, Issue 4, 2006, Pages 252-257

  Kang, G ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Enteric vaccine; Rotavirus; Vaccine

Indexed keywords

'UK'; 116E; BOVINE ROTAVIRUS VACCINE; I 1321; LLR; RIT 4256; ROTAVIRUS VACCINE; RRV; RV 3; UNCLASSIFIED DRUG; WC 3;

DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; GASTROENTERITIS; HUMAN; INDIA; INTUSSUSCEPTION; MORTALITY; REVIEW; SINGLE DRUG DOSE; UNITED STATES; VACCINATION; VIRUS INFECTION;

EID: 33845919374     PISSN: 02550857     EISSN: 02550857     Source Type: Journal    
DOI: 10.4103/0255-0857.29382     Document Type: Review

References (42)

1. th ed. Knipe DM, Howley PM, Griffin DE, editors. Lippincott, Williams and Wilkins: Philadelphia; 2001. p. 1787-833.
2. Ciarlet M, Conner ME, Finegold MJ, Estes MK. Group A rotavirus infection and age-dependent diarrheal disease in rats: A new animal model to study the pathophysiology of rotavirus infection. J Virol 2002;76:41-57.
3. Bresee JS, Glass RI, Ivanoff B, Gentsch J. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 1999;17:2207-22.
4. Ball JM, Tian P, Zeng CQ, Morris AP, Estes MK. Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein. Science 1996;272:101-4.
5. nd ed. Paul P, Francis D, editors. Plenum Press: New York; 1999. p. 73-82.
6. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breue T, Clemens SA, et al. Safety and efficacy of an attenuated vaccine against severe gastroenteritis. N Engl J Med 2006;354:11-22.
7. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santhosham M, Rodriguez Z, et al. Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and Efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006:354:23-33.
8. Bresee J, Fang ZY, Wang B, Nelson EA, Tam J, Soenarto Y, et al. First report from the Asian Rotavirus Surveillance Network. Emerg Inf Dis 2004;10:988-95.
9. Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection. A prospective rotavirus infection against subsequent rotavirus diarrhea. N Engl J Med 1983;309:72-6.
10. World Health Organization. Report of the meeting on the Future Directions for Rotavirus Vaccine Research in Developing Countries. Geneva; 2000 WHO/V and B/.00.23.
11. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003;9:565-72.
12. Kim JS, Kang JO, Cho SC, Jang YT, Min SA, Park TH, et al. Epidemiological profile of rotavirus infection in the Republic of Korea: Results from prospective surveillance in the Jeongeub District, 1 July 2002 through 30 June 2004. J Infect Dis 2005;192:S49-56.
13. Fang ZY, Wang B, Kilgore PE, Bresee JS, Zhang LJ, Sun LW, et al. Sentinel hospital surveillance for rotavirus diarrhea in the People's Republic of China, August 2001-July 2003. J Infect Dis 2005;192:S94-9.
14. Tucker AW, Haddix AC, Bresee JS, Holman RC, Parashar UD, Glass RI. Cost-effectiveness analysis of a rotavirus immunization program for the United States. J Am Med Assoc 1998;279:1371-6.
15. th ed. Knipe DM, Howley PM, Griffin DE, editors. Lippincott, Williams and Wilkins: Philadelphia; 2001. p. 1747-85.
16. Hoshino Y, Kapikian AZ. Classification of rotavirus VP4 and VP7 serotypes. Arch Virol Suppl 1996;12:99-111.
17. Iturriza-Gomara M, Green J, Brown DW, Desselberger U, Gray JJ. Comparison of specific and random priming in the reverse transcriptase polymerase chain reaction for genotyping group A rotaviruses. J Virol Methods 1999;78:93-103.
18. Gentsch JR, Laird AR, Bielfelt B, Griffin DD, Banyai K, Ramachandran M, et al. Serotype diversity and reassortment between human and animal rotavirus strains: Implications for rotavirus vaccine programs. J Infect Dis 2005;192:S146-59.
19. Iturriza-Gomara M, Isherwood B, Desselberger U, Gray J. Reassortment in vivo: Driving force for diversity of human rotavirus strains isolated in the United Kingdom between 1995 and 1999. J Virol 2001;75:3696- 705.
20. Vesikari T, Isolauri E, D'Hondt E, Delem A, Andre FE, Zissis G. Protection of infants against rotavirus diarrhea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984;1:977-81.
21. Bresee JS, Parashar UD, Widdowson MA, Gentsch JR, Steele AD, Glass RI. Update on rotavirus vaccines. Pediatr Infect Dis J 2005;24:947-52.
22. Perez-Schael I, Garcia D, Gonzalez M, Gonzalez R, Daoud R, Perez M, et al. Prospective study of diarrheal diseases in Venezuelan children to evaluate the efficacy of rhesus rotavirus vaccine. J Med Virol 1990;30:219-29.
23. Midthun K, Kapikian AZ. Rotavirus vaccines: An overview. Clin Microbiol Rev 1996;9:423-34.
24. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999;48:1-20.
25. Centers for Disease Control and Prevention (CDC). Intussusception among recipients of rotavirus vaccine - United States, 1998-1999. MMWR Morb Mortal Wkly Rep 1999;48:577-81.
26. Murphy TV, Smith PJ, Gargiullo PM, Schwartz B. The first rotavirus vaccine and intussusceptions: Epidemiological studies and policy decisions. J Infect Dis 2003;187:1309-13.
27. Clark HF, Offit PA, Ellis RW, Eiden JJ, Krah D, Shaw AR, et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis 1996;174:S73-80.
28. Clark HF, Bernstein DI, Dennehy PH, Offit P, Pichichero M, Treanor J, et al. Safety, efficacy and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004;144:184-90.
29. Clements-Mann ML, Makhene MK, Mrukowicz J, Wright PF, Hoshino Y, Midthun K, et al. Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants. Vaccine 1999;17:2715-25.
30. Bernstein DI, Sack DA, Reisinger K, Rothstein E, Ward RL. Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. J Infect Dis 2002;186:1487-9.
31. De Vos B, Vesikari T, Linhares AC, Salinas B, Perez-Schael I, Ruiz-Palacios GM, et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Ped Infect Dis J 2004;23:S179- 82.
32. Barnes GL, Lund JS, Adams L, Mora A, Mitchell SV, Caples A, et al. Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate. J Paediatr Child Health 1997;33:300-4.
33. Das BK, Gentsch JR, Hoshino Y, Ishida S, Nakagomi O, Bhan MK, et al. Characterization of the G serotype and genogroup of New Delhi newborn rotavirus strain 116E. Virology 1993;197:99-107.
34. Das M, Dunn SJ, Woode GN, Greenberg HB, Rao CD. Both surface proteins (VP4 and VP7) of an asymptomatic neonatal rotavirus strain (I321) have high levels of sequence identity with the homologous proteins of a serotype 10 bovine rotavirus. Virology 1993;194:374-9.
35. Iturriza Gomara M, Kang G, Mammen A, Jana AK, Abraham M, Desselberger U, et al. Characterization of G10P[11] rotaviruses causing acute gastroenteritis in neonates and infants in Vellore, India. J Clin Microbiol 2004;42:2541-7.
36. Velazquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell S, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996;335:1022-8.
37. Chiba S, Nakata S, Yokoyama T, Morita Y, Urasawa T, Taniguchi K, et al. Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies. Lancet 1986;2:417-21.
38. Jiang B, Gentsch JR, Glass RI. The role of serum antibodies in the protection against rotavirus disease: An overview. Clin Infect Dis 2002;34:1351-61.
39. Ward RL. Possible mechanisms of protection elicited by candidate rotavirus vaccines as determined by the adult mouse model. Viral Immunol 2003;16:17-24.
40. Yang K, Wang S, Chang KO, Lu S, Saif LJ, Greenberg HB, et al. Immune responses and protection obtained with rotavirus VP6 DNA vaccines given by intramuscular injection. Vaccine 2001;19:3285-91.
41. Crawford SE, Estes MK, Ciarlet M, Barone C, O'Neal CM, Cohen J, et al. Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles. J Virol 1999;73:4813-22.
42. Peter G, Myers MG; National Vaccine Advisory Committee; National Vaccine Program Office. Intussusception, rotavirus and oral vaccines: Summary of a workshop. Pediatrics 2002;110:e67.